Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
Preparing for an influx of cell and gene therapy approvalsCell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has Share XPreparing for an influx of cell and gene therapy approvalshttps://pharmaphorum.com/views-analysis-sales-marketing/preparing-influx-cell-gene-therapy-approvals/
UK accounts for 12% of cell and gene therapy trials – reportThe UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data Share XUK accounts for 12% of cell and gene therapy trials – reporthttps://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Spectacular results for bluebird’s gene therapy in thalassemiaPatients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird Share XSpectacular results for bluebird’s gene therapy in thalassemiahttps://pharmaphorum.com/news/spectacular-results-for-bluebirds-gene-therapy-in-thalassemia/
Kite and Sangamo come together in $3bn cancer gene editing allianceTwo pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious Share XKite and Sangamo come together in $3bn cancer gene editing alliancehttps://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/
Novartis snaps up ex-US partnership with Spark on gene therapyI was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was Share XNovartis snaps up ex-US partnership with Spark on gene therapyhttps://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/
Can Spark make a profit on its groundbreaking gene therapy?Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the Share XCan Spark make a profit on its groundbreaking gene therapy?https://pharmaphorum.com/news/can-spark-make-profit-groundbreaking-gene-therapy/
Sangamo edits living patient’s DNA for first timeDoctors in California have made history by attempting to edit genes within a patient for the first time, Share XSangamo edits living patient’s DNA for first timehttps://pharmaphorum.com/news/us-doctors-gene-editing/
